Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24722333 | 0.85 | CCNB2 (0.41) | KDRBRD4ADORA2AADORA3ADORA1 | |
| SCHEMBL23046742 | 0.78 | CCNB2 (0.39) | KDRADORA2AADORA3ADORA1 | |
| SCHEMBL20857311 | 0.78 | CCNB2 (0.39) | KDREGFRMAPK14ADORA2AADORA3 | |
| SCHEMBL14438661 | 0.76 | BRD4 (0.47) | CSF1RKDRRETAURKBEGFR | |
| SCHEMBL12031146 | 0.75 | PRMT5 (0.40) | KDRADORA2A | |
| SCHEMBL21413054 | 0.73 | CSF1R (0.35) | CSF1RKDRRETAURKBAURKA | |
| SCHEMBL25996317 | 0.72 | CSF1R (0.43) | CSF1RKDRRETAURKBIRAK4 | |
| SCHEMBL25605575 | 0.72 | CCNB2 (0.39) | KDRAURKBIRAK4BRD4ADORA2A | |
| SCHEMBL27430176 | 0.71 | CDK1 (0.63) | ADORA2AADORA3ADORA1TMIGD3 | |
| SCHEMBL25605574 | 0.71 | CCNB2 (0.38) | KDRAURKBAURKAIRAK4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-11-03 | — | — | US | disclosed |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | CSF1R 859/4885KDR 2236/4885RET 3186/4885 |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | CSF1R 859/4885KDR 2236/4885RET 3186/4885 |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | CSF1R 859/4885KDR 2236/4885RET 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.